Lumeris

News

In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment stories from across the industry.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.